Vandetanib and the management of advanced medullary thyroid cancer

Michael Campbell, Carolyn D. Seib, Jessica Gosnell

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


PURPOSE OF REVIEW: Vandetanib is a small molecule tyrosine kinase inhibitor that has been recently approved as an 'orphan drug' for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). RECENT FINDINGS: MTC is a neuroendocrine malignancy frequently associated with mutations to the RET proto-oncogene. Vandetanib selectively targets RET, vascular endothelial growth factor receptor-2, and epidermal growth factor receptor dependent signaling. Vandetanib has been shown to improve progression-free survival in patients with advanced MTC. In general, vandetanib is well tolerated, but QTc prolongation remains a potential concern demanding careful patient selection and monitoring. SUMMARY: Vandetanib has emerged as one of the more promising small molecule tyrosinse kinase inhibitors, providing durable rates of disease stabilization, with an acceptable adverse event profile in patients with advanced MTC.

Original languageEnglish (US)
Pages (from-to)39-43
Number of pages5
JournalCurrent Opinion in Oncology
Issue number1
StatePublished - Jan 2013


  • Medullary thyroid cancer
  • Tyrosine kinase inhibitor
  • Vandetanib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Vandetanib and the management of advanced medullary thyroid cancer'. Together they form a unique fingerprint.

Cite this